miR-195-3p alleviates atherosclerosis by regulating VSMC functions through JNK2/NF-κB pathway
This study demonstrates that miR-195-3p alleviates atherosclerosis by directly targeting JNK2 to inhibit the NF-κB inflammatory cascade, thereby suppressing pathological vascular smooth muscle cell dysfunction and reducing plaque burden.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body is a vast network of pipes, carrying life-sustaining blood to every corner. When these pipes become clogged with fatty deposits, a condition known as atherosclerosis, the risk of heart attack or stroke rises dramatically. This clogging is not merely a passive buildup of grease; it is an active, chaotic process driven by the cells that line the vessel walls. Among these, vascular smooth muscle cells act as the structural framework of the arteries. In a healthy state, these cells are calm and contractile, holding the vessel open and maintaining its shape. However, when exposed to high levels of fat or inflammation, they undergo a dangerous transformation. They lose their stability, begin to multiply rapidly, migrate into the wrong areas, and secrete chemicals that fuel further inflammation. This shift from a stable guardian to a chaotic builder is a primary engine behind the growth of arterial plaques. Understanding how to stop this transformation, or even reverse it, is a central goal for researchers trying to prevent cardiovascular disease.
Scientists have long known that tiny molecules called microRNAs act as master switches inside cells, turning other genes on or off to control behavior. One specific molecule, miR-195-3p, had been suspected of having a protective role in the heart, but its exact job within the smooth muscle cells remained a mystery. A team of researchers set out to solve this puzzle, investigating whether this tiny molecule could act as a brake on the dangerous changes happening in the arteries. They began by looking at real-world evidence, measuring levels of miR-195-3p in the blood of patients with coronary artery disease and in the arteries of mice fed a high-fat diet. In both cases, the protective molecule was missing in large amounts, suggesting that its absence might be linked to the disease.
To see what happens when this molecule is present, the researchers turned to laboratory cultures of human smooth muscle cells. They introduced extra miR-195-3p into these cells and watched what changed. The results were striking. The cells that received the extra molecule stopped multiplying as quickly and stopped moving around as much. Instead of becoming the chaotic, synthetic builders seen in disease, they held onto their calm, contractile identity. They also stopped releasing the inflammatory chemicals that usually attract immune cells and worsen the blockage. Conversely, when the researchers blocked the molecule, the cells behaved aggressively, multiplying and migrating as if they were in a diseased state. This confirmed that miR-195-3p is a powerful regulator that keeps these cells in a healthy, stable state.
The team then asked how this tiny molecule exerts such a strong influence. They searched for the specific target inside the cell that miR-195-3p binds to, much like a key fitting into a lock. They identified a protein called JNK2 as the direct target. In healthy cells, miR-195-3p binds to the instructions for making JNK2 and prevents the protein from being produced. When miR-195-3p is missing, JNK2 levels rise. The researchers found that high levels of JNK2 act as a trigger for a chain reaction that leads to cell dysfunction. Specifically, JNK2 activates another pathway known as NF-κB, which is a major driver of inflammation and the switch to the dangerous synthetic state. By blocking JNK2, miR-195-3p effectively cuts off the signal that tells the cells to become unstable and inflamed.
To prove that this mechanism works in a living organism, the researchers used a safe viral vector to deliver the miR-195-3p molecule directly into the bloodstream of mice that had been fed a high-fat diet to induce heart disease. Over a period of twenty weeks, the mice that received the treatment developed significantly smaller fatty plaques in their arteries compared to the untreated mice. The treatment successfully lowered the levels of the harmful JNK2 protein and the inflammatory NF-κB signal within the artery walls. It also restored the balance of the smooth muscle cells, helping them return to their stable, contractile form. The blood of these treated mice also showed lower levels of inflammatory markers, mirroring the changes seen in the laboratory cells.
This work connects several pieces of a complex biological puzzle. It shows that the absence of miR-195-3p allows a specific protein, JNK2, to rise unchecked, which in turn turns on a powerful inflammatory switch that drives artery-clogging disease. By restoring miR-195-3p, the researchers were able to shut down this entire cascade, protecting the blood vessels from damage. While this study was conducted in cells and mice, and more research is needed to see if the same approach works in humans, it offers a clear new path for understanding how arteries stay healthy. It suggests that therapies designed to boost this specific molecule could one day help prevent or treat the arterial blockages that lead to heart attacks and strokes.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.